Research Progress on Chemoresistance Mechanism of Nuclear Factor Kappa B Signalling Patheway in Acute Myeloid Leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1785-1790, 2015.
Artigo
em Chinês
| WPRIM
| ID: wpr-272521
ABSTRACT
Acute myeloid leukemia (AML) is the most common leukemia in adult, among them the childhood acute myeloid leukemia accounts for 15% to 20%. After exploring and investigating this disease for 60 years, the systematic chemotherapy can achieve complete remission for 75%-80% AML patients, but only 20%-30% AML patients out of them can be cured, and other AML patients relapsed or died of this disease. The primary and/or seondary chemotherapy resistance may be the main reasons of the poor prognosis in AML. The activity of nuclear factor kappa B (NF-κB) involved into multi-layers of physiological functions. Among them, the activity of NF-κB and the apoptosis toleration associated with the sensitivity to chemotherapy. All these indicated that the inhibition of NF-κB may be a promising direction to reverse chemoresistance and improve chemotherapeutic effects for AML. Herein is the review of recent research progress on the field of the roles of NF-κB activation in AML and its application in AML therapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Indução de Remissão
/
Leucemia Mieloide Aguda
/
Transdução de Sinais
/
NF-kappa B
/
Apoptose
/
Resistencia a Medicamentos Antineoplásicos
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS